The effect of human serum albumin glycation on the binding of antidiabetic agent-exenatide; the multispectroscopic studies. Part II.
Biophys Chem · 2023
Last updated 2026-05-28A lab study found that the diabetes drug exenatide binds to glycated human serum albumin with association values of 4.57 × 10⁻⁵ M at 290K, 3.33 × 10⁻⁵ M at 300K, and 2.54 × 10⁻⁵ M at 310K, with about 1 binding site per protein molecule. The binding happens naturally and is mainly driven by electrostatic forces. Adding metal ions like calcium, chromium, or zinc increased the drug’s binding strength to the protein, while exenatide alone had little effect on the protein’s structure.
AI summary of the abstract below.
| Journal | Biophys Chem, 2023 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.63 |
| NIH percentile | 36 |
| Molecules | exenatide |
| Conditions studied | Type 2 Diabetes |
Abstract
The glycated human serum albumin (gHSA) interaction with antidiabetic agent - exenatide (exe) was investigated by spectroscopic techniques. The fluorescence spectroscopy showed an association between exe and protein as 4.57 × 10 M (290 K), 3.33 × 10 M (300K) and 2.54 × 10 M (310K) and the number of binding sites were 1.15, 1.09, and 1.02, respectively. The binding process occurred spontaneously and the electrostatic bonds play a predominant role in the gHSA-exe interaction. The affinity drug to gHSA was studied in the presence of metal ions (Ca, Cr, Zn), which are often given as a supplement to the diet. Our study indicates that metal ions have an effect on the increase of the affinity of exenatide to glycated albumin and it is the result of the metal ion-exenatide-albumin interaction. Based on CD spectroscopy it is evident that exenatide has nonsignificant effect on the protein secondary structure, but the changes are visible in the presence of metal ions. Zeta potential measurements indicate instability of the system at lower concentration of the ligand - the effect is desired in point of view of pharmacology.
Verbatim abstract via PubMed 36621076 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.